IKK is a therapeutic target in KRAS-induced lung cancer with disrupted p53 activity

Daniela S. Daniela Sanchez Bassères(UNC Lineberger Comprehensive Cancer Center), Albert S. Baldwin(University of North Carolina at Chapel Hill)
Genes & Cancer
April 21, 2014
Cited by 35


Related Papers